Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)

Recruiting now

Conditions studied: Acute Myeloid Leukemia, AML, Adult, Acute Myeloid Leukemia, Adult

In brief

This multicenter, prospective and retrospective observational study aims to evaluate the use and efficacy of new drugs or their combinations in real-life in a population of adult AML patients.

Key facts

Study ID

NCT06513273

Run by

Gruppo Italiano Malattie EMatologiche dell'Adulto

People needed

397

Starts

2025-07-11

Expected to finish

2029-12-01

Last updated by the study team

2025-08-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18 years or older
• AML diagnosis according to the ELN guidelines, excluding M3
• Signed Informed consent, if applicable
• Treatment initiation with novel drugs in monotherapy or combination, in accordance with the AIFA authorizations, from the AIFA registration up to 31.12.2027 with particular attention to:
• patients affected by FLT3-mutated AML treated with gilteritinib.
• patients affected by IDH-mutated AML treated with IDH inhibitors.
• patients affected by AML in maintenance therapy with oral azacytidine.
• patients affected by AML treated with glasdegib.
• patients affected by AML treated with gemtuzumab ozogamicin.
• other novel drugs or combination for the treatment of AML approved during the study period.

You may not qualify if…

• Patients included in interventional clinical trials.

Where it is running

• Ematologia Ente Ecclesiastico Casa Sollievo Della Sofferenza — San Giovanni Rotondo, Italy (enrolling)
• UOC Ematologia AOU di SASSARI — Sassari, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.